Literature DB >> 3312999

Mechanism of formation and quantitation of imines, pyrroles, and stable nonpyrrole adducts in 2,5-hexanedione-treated protein.

A P DeCaprio1, S J Jackowski, K A Regan.   

Abstract

The condensation of gamma-diketones with protein epsilon-amino moieties to yield alkylpyrrole adducts has been demonstrated in many in vitro and in vivo systems, although certain features of this reaction remain unclear. The present in vitro study was designed to examine additional aspects of gamma-diketone-protein interactions, including the possible formation of imine intermediates and stable nonpyrrole products, and the potential for conformational changes in pyrrolylated protein. Values for total, stable covalent binding were consistently higher than p-dimethylaminobenzaldehyde (DMAB)-detectable pyrrole adduct concentrations when bovine serum albumin (BSA) was incubated (24 hr, 37 degrees C) with [14C]-2,5-hexanedione (2,5-HD) at diketone:lysine ratios greater than or equal to 5:1 (at pH 9.5) or 1:1 (at pH 7.4). Treatment of pyrrolylated BSA with proteases before the DMAB assay decreased but did not eliminate the difference between these parameters. Quantitative amino acid analysis of pyrrolylated BSA revealed molar decreases in lysine content equivalent to DMAB-detectable pyrrole adduct concentrations; no other amino acids were significantly altered. Cleavage of disulfide bonds in pyrrolylated BSA by dithiothreitol resulted in an apparent decrease in DMAB-detectable pyrrole, which was reversible upon subsequent protease treatment. A similar decrease was not seen with pyrrolylated concanavalin A, a protein that lacks disulfide linkages. Samples of BSA were incubated with [14C]-2,5-hexanedione for 2-144 hr and a portion of each incubation mixture treated with NaCNBH3 to selectively reduce imines to stable amines. Substantial levels of an imine intermediate were detected at 2, 6, and 24 hr but not at 144 hr. The above findings support proposed mechanisms involving imine intermediates in the pyrrolylation reaction. In addition, evidence for the formation of stable nonpyrrole adducts at high diketone:amine molar ratios has been provided. Results consistent with potential conformational alterations in pyrrolylated protein have also been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312999

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

Review 1.  Toxic neuropathies: Mechanistic insights based on a chemical perspective.

Authors:  Richard M LoPachin; Terrence Gavin
Journal:  Neurosci Lett       Date:  2014-09-16       Impact factor: 3.046

2.  Proximal giant neurofilamentous axonopathy in mice genetically engineered to resist calpain and caspase cleavage of α-II spectrin.

Authors:  R Kassa; V Monterroso; J Wentzell; A L Ramos; E Couchi; M C Lecomte; M Iordanov; D Kretzschmar; G Nicolas; D Tshala-Katumbay
Journal:  J Mol Neurosci       Date:  2012-01-03       Impact factor: 3.444

3.  Golgi-modifying properties of macfarlandin E and the synthesis and evaluation of its 2,7-dioxabicyclo[3.2.1]octan-3-one core.

Authors:  Martin J Schnermann; Christopher M Beaudry; Anastasia V Egorova; Roman S Polishchuk; Christine Sütterlin; Larry E Overman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-23       Impact factor: 11.205

4.  Synthesis and structural characterization of carboxyethylpyrrole-modified proteins: mediators of age-related macular degeneration.

Authors:  Liang Lu; Xiaorong Gu; Li Hong; James Laird; Keeve Jaffe; Jaewoo Choi; John Crabb; Robert G Salomon
Journal:  Bioorg Med Chem       Date:  2009-09-13       Impact factor: 3.641

5.  Metabolomics and mass isotopomer analysis as a strategy for pathway discovery: pyrrolyl and cyclopentenyl derivatives of the pro-drug of abuse, levulinate.

Authors:  Stephanie R Harris; Guo-Fang Zhang; Sushabhan Sadhukhan; Hua Wang; Chuan Shi; Michelle A Puchowicz; Vernon E Anderson; Robert G Salomon; Gregory P Tochtrop; Henri Brunengraber
Journal:  Chem Res Toxicol       Date:  2012-12-06       Impact factor: 3.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.